ArticleToxics2025
Bioinformatic Evidence Suggesting a Dopaminergic-Related Molecular Association Between GenX Exposure and Major Depressive Disorder.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
With the increasing global burden of major depressive disorder (MDD), identifying modifiable environmental risk factors has become a critical priority. Per- and polyfluoroalkyl substances (PFASs), characterized by environmental persistence and bioaccumulation, have been linked to elevated mental health risks. However, the potential neurotoxicity of GenX-a novel PFAS developed to replace perfluorooctanoic acid (PFOA)-and its molecular association with MDD remain unclear. In this study, peripheral blood serum transcriptomic data from the Gene Expression Omnibus (GEO) were integrated with multidimensional bioinformatics analyses to elucidate molecular mechanisms connecting GenX exposure with MDD. Four hub genes (UCP2, AKR1B1, TP53, and F5) were identified, showing strong combined diagnostic performance (AUC = 0.925). Functional enrichment and immune infiltration analyses revealed their involvement in energy metabolism, oxidative stress, and immune-coagulation regulation. Molecular docking and dynamics simulations further confirmed stable interactions between GenX and these proteins, providing structural support for their mechanistic roles. Although classical dopaminergic markers (TH, SLC6A3, DRD1-5) were not detected in the serum-derived transcriptomes, the identified hub genes may still affect dopaminergic function indirectly by modulating metabolic, oxidative stress, and inflammatory/coagulation pathways, thereby influencing MDD susceptibility. This study provides the first integrated transcriptomic and structural evidence linking GenX to psychiatric risk, proposing a novel "GenX-dopamine-MDD" framework for understanding pollutant-mediated neuropsychiatric mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.